|
Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1 therapy in squamous cell carcinoma of the head and neck. |
|
|
|
Stock and Other Ownership Interests - Personalis |
Research Funding - Personalis |
Travel, Accommodations, Expenses - Personalis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Personalis |
Research Funding - Personalis |
Travel, Accommodations, Expenses - Personalis |
|
|
|
Research Funding - Personalis |
Travel, Accommodations, Expenses - Personalis |
|
|
|
Stock and Other Ownership Interests - Personalis |
Research Funding - Personalis |
Travel, Accommodations, Expenses - Personalis |
|
|
Consulting or Advisory Role - Merck; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Gilead Sciences |
Consulting or Advisory Role - Aduro Biotech; ATARA Biotherapeutics; COTA; CUE Biopharma; grand rounds; IQvia; IQvia; KeyQuest Health; Loxo; PDS Biotechnology; Pfizer; PRA Health Sciences; Rakuten Medical; Roche; Taiho Oncology |
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; Bristol-Myers Squibb; Cellsight Technologies; Cullinan Oncology; Exelixis; Innate Pharma; NIH/NCI; Novartis; Roche; Tessa Therapeutics |
|
|
|
|
Stock and Other Ownership Interests - Personalis |
Patents, Royalties, Other Intellectual Property - Multiple Personalis technology patents |
Travel, Accommodations, Expenses - Personalis |
|
|
|
Stock and Other Ownership Interests - Personalis |
Research Funding - Personalis |
Travel, Accommodations, Expenses - Personalis |